China’s Innovent Strikes $1.14 Billion Cancer Drug Deal with Pharma Giant Takeda
hinese biotech company Innovent Biologics has signed a massive deal with Japan’s Takeda Pharmaceutical. The agreement is valued up to $1.14 billion. This partnership focuses on developing and commercializing a promising new cancer therapy. This collaboration highlights the growing importance of China’s biomedical sector. Innovent will lead the development and regulatory filings in mainland China….